Table 5: Clinical characteristics of NMO patients with in relation to the significant HLA alleles and Human promoter TNF alpha polymorphisms.
Variables | HLA DRB1 *10:01 |
HLA DRB1 *11:01 - 11:04 |
HLA DQA1 *03:01 |
pTNF-a SNPs 308G/A |
||||
(+) N = 2 |
(-) N = 18 |
(+) N = 9 |
(-) N = 11 |
(+) N = 3 |
(-) N = 17 |
A vs. G F = 0.38 F = 0.77 |
||
AO (years)* P value |
29.8 ± 11.3 | 37 ± 2 | 27.7 ± 10.3 | 13.3 ± 4.2 | 19.0 ± 5.6 | 11.8 ± 2.8 | 25.5 ± 13.9 | 29.7 ± 11.4 |
P = 0.446 | P = 0.47 | P = 0.17 | P = 0.430 | |||||
DOD (years)* P value |
6.7 ± 4.4 | 7.4 ± 2.2 | 7.2 ± 1.94 | 7.0 ± 1.05 | 4.6 ± 0.66 | 7.47 ± 1.13 | 8.42 ± 2.43 | 7.33 ± 1.18 |
P = 0.316 | P = 0.66 | P = 0.14 | P = 0.783 | |||||
NR* P value |
3.31 ± 2.10 | 2.5 ± 0.7 | 3.44 ± 5.8 | 3.20 ± 7.85 | 3.5 ± 1.5 | 3.29 ± 5.26 | 2.21 ± 0.78 | 3.4 ± 0.6 |
P = 0.84 | P = 0.31 | P = 0.84 | P = 0.891 | |||||
TM (%) P value |
1 (5) | 9 (45) | 3 (33.3) | 6 (60) | 2 (10) | 7 (35) | 3 (15) | 12 (60) |
P = 0.526 | P = 0.242 | P = 0.211 | P = 0.15 | |||||
ON (%) P value |
1 (5) | 6 (30) | 3 (33.3) | 3 (30) | 1 (5) | 6 (30) | 4 (20) | 8 (40) |
P = 0.684 | P = 0.630 | P = 0.456 | P = 0.88 |
*: Means ± SD, pTNF-a: TNF alpha polymorphisms; F: Frequencies of alleles A and G; AO: Age at Onset;
DOD: Duration of Disease; NR: Number of Relapses; TM: Transverse Myelitis; ON: Optic Neuritis.